info@projectetris.eu

Project Partners

Neolys Diagnostics

Neolys Diagnostics is a Biotechnology company specialized in precision medicine for radiation oncology, Neolys Diagnostics develops innovative medical tests combining DNA repair biomarkers and radiotherapy treatment parameters to anticipate and reduce treatment-related side effects, optimize therapeutic efficacy, and contribute to healthcare cost reduction through personalized radiotherapy strategies. 

Dr. Pereira, Sandrine is the Scientific Director of Neolys Diagnostics. With over 15 years of experience in radiosensitivity testing and oncology innovation, Sandrine Pereira leads Work Package 8 (WP8) within the TETRIS Project, ensuring scientific coherence between functional biomarkers, genetic data, and clinical application. Her Team members are Mathilde Hà-Lasnon and Laura Desrivot. 

Neolys Diagnostics – WP8 Leadership: Cellular Sensitivity Testing in the TETRIS Prospective Cohort. 
WP8 focuses on the assessment of cellular radiosensitivity and the integration of functional biomarkers with genetic information, including Polygenic Risk Scores (PRS) derived from SNP analysis, enabling multidimensional patient risk profiling. RadioDTect© and RadioProfile© Assays are Functional radiosensitivity testing assays. The RadioDTect© blood test and RadioProfile© skin test are performed on biological samples collected using standardized protocols from patients enrolled in the TETRIS prospective cohort (WP9). 

Neolys Diagnostics is also part of WP4-Integration of functional and genomic data and WP7- Biological input for Digital Twin development. WP9 – Prospective collection and WP10 – Dissemination and Exploitation. 

Visit Website

Follow Us

@projectetris

🧩 Inside the TETRIS Consortium

Neolys Diagnostics is a biotechnology company specialised in precision medicine for radiation oncology. Neolys develops innovative medical tests combining DNA repair biomarkers with radiotherapy treatment parameters to anticipate and reduce treatment-related side effects, optimise therapeutic efficacy, and support more personalised radiotherapy strategies.

Within the TETRIS project, Neolys contributes its expertise in functional radiosensitivity testing and oncology innovation under the leadership of Sandrine Pereira, Scientific Director of Neolys Diagnostics.

Neolys leads:
🧪 WP8 – Cellular Sensitivity Testing in the TETRIS Prospective Cohort, focused on assessing cellular radiosensitivity and integrating functional biomarkers with genetic information, including Polygenic Risk Scores (PRS) derived from SNP analysis, to enable multidimensional patient risk profiling.

🔗 Learn more about Neolys Diagnostics and its role in the TETRIS project on our website 🌐 urlr.me/wCdGxf

2 0
Open post by projectetris with ID 17935825776159077
🧩 Inside the TETRIS Consortium Neolys Diagnostics is a biotechnology company specialised in precision medicine for radiation oncology. Neolys develops innovative medical tests combining DNA repair biomarkers with radiotherapy treatment parameters to anticipate and reduce treatment-related side effects, optimise therapeutic efficacy, and support more personalised radiotherapy strategies. Within the TETRIS project, Neolys contributes its expertise in functional radiosensitivity testing and oncology innovation under the leadership of Sandrine Pereira, Scientific Director of Neolys Diagnostics. Neolys leads: 🧪 WP8 – Cellular Sensitivity Testing in the TETRIS Prospective Cohort, focused on assessing cellular radiosensitivity and integrating functional biomarkers with genetic information, including Polygenic Risk Scores (PRS) derived from SNP analysis, to enable multidimensional patient risk profiling. 🔗 Learn more about Neolys Diagnostics and its role in the TETRIS project on our website 🌐 urlr.me/wCdGxf

...

2 0

📢 Thank you for joining the first TETRIS Educational Webinar!

A big thank you to everyone who participated in the first webinar of the TETRIS Educational Webinar Series, delivered by Eva Onjukka and Filippo Schiavo, from Karolinska University Hospital, and moderated by Tiziana Rancati, Project Investigator of the TETRIS project, from Fondazione IRCCS Istituto Nazionale dei Tumori.

Key takeaways from the webinar:
· radiation-induced side effects in patients treated with radiotherapy and on how these outcomes are measured using clinician- and patient-reported scales.
· importance of evaluating model performance, with a strong emphasis on calibration, crucial for communicating absolute risk to patients, alongside discrimination metrics

🔁 Missed the webinar or would like to watch it again?
Read the full news on our website here urlr.me/t8nvBQ and access the full recording on TETRIS YouTube channel.

We look forward to welcoming you to the next TETRIS Educational Webinars!

@Karolinska Universitetssjukhuset @karolinskaunivsjukh @istituto_tumori

2 0
Open post by projectetris with ID 18362077798166380
📢 Thank you for joining the first TETRIS Educational Webinar! A big thank you to everyone who participated in the first webinar of the TETRIS Educational Webinar Series, delivered by Eva Onjukka and Filippo Schiavo, from Karolinska University Hospital, and moderated by Tiziana Rancati, Project Investigator of the TETRIS project, from Fondazione IRCCS Istituto Nazionale dei Tumori. Key takeaways from the webinar: · radiation-induced side effects in patients treated with radiotherapy and on how these outcomes are measured using clinician- and patient-reported scales. · importance of evaluating model performance, with a strong emphasis on calibration, crucial for communicating absolute risk to patients, alongside discrimination metrics 🔁 Missed the webinar or would like to watch it again? Read the full news on our website here urlr.me/t8nvBQ and access the full recording on TETRIS YouTube channel. We look forward to welcoming you to the next TETRIS Educational Webinars! @Karolinska Universitetssjukhuset @karolinskaunivsjukh @istituto_tumori

...

2 0

📢 TETRIS Educational Series. Second Webinar

Following the great participation from our first TETRIS educational webinar, we are pleased to announce that we are ready for the second event of the series.

🗓 Friday, 27 February
⏰ 13:00–14:00 CET

In this second webinar, Claudio Fiorino and Martina Mori from Università Vita-Salute San Raffaele UniSR, will present “Methods for assessing imaging biomarkers in breast cancer radiotherapy within the TETRIS project”
This session will focus on methodological approaches for evaluating imaging biomarkers in breast cancer radiotherapy, highlighting their role within the TETRIS project to support personalised risk assessment and safer treatment pathways.

👉 To join click here: the session urlr.me/QRzacM.

We look forward to welcoming you to the second appointment of the TETRIS Educational Series. @unisr @Università Vita-Salute San Raffaele @ospedalesanraffaele @IRCCS Ospedale San Raffaele

Image “Designed by Freepik”, www.freepik.com.

1 0
Open post by projectetris with ID 17988724994925458
📢 TETRIS Educational Series. Second Webinar Following the great participation from our first TETRIS educational webinar, we are pleased to announce that we are ready for the second event of the series. 🗓 Friday, 27 February ⏰ 13:00–14:00 CET In this second webinar, Claudio Fiorino and Martina Mori from Università Vita-Salute San Raffaele UniSR, will present “Methods for assessing imaging biomarkers in breast cancer radiotherapy within the TETRIS project” This session will focus on methodological approaches for evaluating imaging biomarkers in breast cancer radiotherapy, highlighting their role within the TETRIS project to support personalised risk assessment and safer treatment pathways. 👉 To join click here: the session urlr.me/QRzacM. We look forward to welcoming you to the second appointment of the TETRIS Educational Series. @unisr @Università Vita-Salute San Raffaele @ospedalesanraffaele @IRCCS Ospedale San Raffaele Image “Designed by Freepik”, www.freepik.com.

...

1 0